Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name FGFR2 - KIAA1217
Gene Variant Detail

FGFR2 - KIAA1217 (gain of function - predicted)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR2 - KIAA1217 Advanced Solid Tumor sensitive Pemigatinib Preclinical - Cell culture Actionable In a preclinical study, Pemazyre (pemigatinib) treatment decreased viability of transformed cells expressing FGFR2-KIAA1217 in culture (PMID: 35176488). 35176488
FGFR2 - KIAA1217 cholangiocarcinoma predicted - sensitive Pemigatinib Case Reports/Case Series Actionable In a Phase II trial (FIGHT-202), Pemazyre (pemigatinib) treatment in a cholangiocarcinoma patient harboring FGFR2-KIAA1217 resulted in a partial response with a decrease in tumor size of 60.5% and progression-free survival of 15.9 months (PMID: 33218975; NCT02924376). 33218975
FGFR2 - KIAA1217 intrahepatic cholangiocarcinoma predicted - sensitive Derazantinib Case Reports/Case Series Actionable In a Phase Ib/II trial, treatment with Derazantinib (ARQ 087) in two patients with intrahepatic cholangiocarcinoma harboring FGFR2-KIAA1217 resulted in one with a partial response and one with stable disease (PMID: 30420614; NCT01752920). 30420614
FGFR2 - KIAA1217 cholangiocarcinoma sensitive Infigratinib Case Reports/Case Series Actionable In a clinical case study, treatment with Truseltiq (infigratinib) resulted in stable disease for 6.6 months in a patient with cholangiocarcinoma harboring an FGFR2-KIAA1217 fusion (PMID: 34250419). 34250419
FGFR2 - KIAA1217 cholangiocarcinoma sensitive Infigratinib Case Reports/Case Series Actionable In a clinical case study, treatment with Truseltiq (infigratinib) resulted in stable disease for 10.6 months in a patient with cholangiocarcinoma harboring an FGFR2-KIAA1217 fusion (PMID: 34250419). 34250419
FGFR2 - KIAA1217 cholangiocarcinoma predicted - sensitive Debio 1347 Case Reports/Case Series Actionable In a Phase I trial, Debio 1347 treatment resulted in stable disease in a patient with cholangiocarcinoma harboring FGFR2-KIAA1217 (PMID: 30745300; NCT01948297). 30745300
FGFR2 - KIAA1217 intrahepatic cholangiocarcinoma sensitive Futibatinib Preclinical - Pdx Actionable In a preclinical study, TAS-120 treatment of an intrahepatic cholangiocarcinoma patient-derived xenograft model, harboring an FGFR2-KIAA1217 fusion, decreased tumor growth and suppressed MEK/ERK signaling (PMID: 31109923). 31109923
FGFR2 - KIAA1217 intrahepatic cholangiocarcinoma sensitive Futibatinib Case Reports/Case Series Actionable In a Phase I trial, Futibatinib (TAS-120) treatment at a dose of 16mg led to a partial response in 42.1% (8/19) of patients with intrahepatic cholangiocarcinoma harboring FGF or FGFR alterations, including a partial response with a progression-free survival of 6.8 months and a duration of response of 5.6 months in a patient harboring FGFR2-KIAA1217 (PMID: 34551969; NCT02052778). 34551969
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries